X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to develop next-generation sequencing-based companion diagnostic assays to identify patients who may benefit from Bayer’s portfolio of precision cancer therapies, including Nubeqa (darolutamide), a medication for certain prostate cancers (mHSPC, nmCRPC).
Lead Product(s): Darolutamide
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 20, 2024
Details:
Under the terms of the agreement, Thermo Fisher will provide GMP manufacturing as well as BioServices and Specialty Logistics for Galapagos’ CAR-T hemato-oncology clinical program, GLPG-5101, being developed for the treatment of Non-Hodgkin’s lymphoma.
Lead Product(s): GLPG-5101
Therapeutic Area: Oncology Product Name: GLPG-5101
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Galapagos
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 04, 2024
Details:
ASLAN004 (eblasakimab) is a potential first-in-class monoclonal antibody targeting the IL-13 receptor that has the potential to deliver a differentiated efficacy and safety profile for the treatment of moderate-to-severe atopic dermatitis (AD).
Lead Product(s): Eblasakimab
Therapeutic Area: Dermatology Product Name: ASLAN004
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: ASLAN Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 03, 2023
Details:
As part of this expanded agreement, Thermo Fisher will now provide dedicated capacity for a range of aseptic fill-finish services including lyophilized and liquid filling for Spikevax. In addition, the company will provide inspection, labeling and final packaging services.
Lead Product(s): Elasomeran
Therapeutic Area: Infections and Infectious Diseases Product Name: Spikevax
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 23, 2022
Details:
This agreement is part of Merck’s commitment to make this investigational medicine widely available globally, if approved for use by regulatory agencies. Molnupiravir is being developed by Merck in collaboration with Ridgeback Biotherapeutics.
Lead Product(s): Molnupiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: MK-4482
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 06, 2021
Details:
Thermo Fisher’s commercial manufacturing site in Greenville, North Carolina will be used for aseptic fill/finish, labeling and packaging to support the production of millions of doses of mRNA-1273. Production will begin in the third quarter of 2021.
Lead Product(s): mRNA-1273
Therapeutic Area: Infections and Infectious Diseases Product Name: Spikevax
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 01, 2021
Details:
The Partnership will support the clinical development and commercial manufacturing of leading CAR-T (Chimeric Antigen Receptor T-Cells) therapies in China, including JW Therapeutics’ lead product relmacabtagene autoleucel (“relma-cel”).
Lead Product(s): Relmacabtagene autoleucel
Therapeutic Area: Oncology Product Name: Relma-cel
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: JW Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 03, 2021
Details:
Freeline has established the manufacturing process for FLT180a at Thermo Fisher’s Cambridge facility over the past two years, most recently initiating clinical supply production there for its planned Phase 2b/3 pivotal clinical trial of FLT180a.
Lead Product(s): FLT180a
Therapeutic Area: Genetic Disease Product Name: FLT180a
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Freeline Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 23, 2020
Details:
The partnership adds to Humanigen’s large scale commercial production efforts, including collaborations with Lonza and Catalent, for a potential 2020 EUA and subsequent commercialization of lenzilumab.
Lead Product(s): Lenzilumab
Therapeutic Area: Infections and Infectious Diseases Product Name: Humaneered
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Humanigen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 23, 2020
Details:
Approval by the MHLW would accelerate access to Chugai's targeted therapy via a locally administered, next-generation sequencing (NGS) biomarker test.
Lead Product(s): Entrectinib
Therapeutic Area: Oncology Product Name: Rozlytrek
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Chugai Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
